title: Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
abstract: Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.
authors.affiliation: Division of Nephrology, Hofstra Northwell School of Medicine, Great Neck, New York.
authors.forename: Rimda
authors.initials: R
authors.lastname: Wanchoo
authors.affiliation: Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Ala
authors.initials: A
authors.lastname: Abudayyeh
authors.affiliation: Division of Nephrology, Wayne State University School of Medicine, Detroit, Michigan.
authors.forename: Mona
authors.initials: M
authors.lastname: Doshi
authors.affiliation: Kidney Diseases Branch, National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland.
authors.forename: Amaka
authors.initials: A
authors.lastname: Edeani
authors.affiliation: Department of Medicine, Renal Service, Memorial Sloan Kettering Cancer Center and Department of Medicine, Weill Cornell Medical Center, New York, New York.
authors.forename: Ilya G
authors.initials: IG
authors.lastname: Glezerman
authors.affiliation: Nephrology Division, University of Mississippi Medical Center, Jackson, Mississippi; and.
authors.forename: Divya
authors.initials: D
authors.lastname: Monga
authors.affiliation: Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Rosner
authors.affiliation: Division of Nephrology, Hofstra Northwell School of Medicine, Great Neck, New York.
authors.forename: Kenar D
authors.initials: KD
authors.lastname: Jhaveri
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D000069286:Bortezomib / Q000009:adverse effects; D000068338:Everolimus / Q000009:adverse effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007155:Immunologic Factors / Q000009:adverse effects*; D007211:Indoles / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D000077594:Nivolumab; D009842:Oligopeptides / Q000009:adverse effects; D010091:Oximes / Q000009:adverse effects; D061988:Proteasome Inhibitors / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007093:Imidazoles; D007155:Immunologic Factors; D007211:Indoles; D009842:Oligopeptides; D010091:Oximes; D061988:Proteasome Inhibitors; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; C546027:elotuzumab; D000077484:Vemurafenib; D000077594:Nivolumab; D013792:Thalidomide; C558235:IPH-2101; D000069286:Bortezomib; C524865:carfilzomib; D000068338:Everolimus; C467566:pomalidomide; C582435:pembrolizumab; D000077269:Lenalidomide; C561627:dabrafenib; C504234:siltuximab
keywords: Acute Kidney Injury; Antibodies, Monoclonal; Coal Tar; Proteasome Inhibitors; Water-Electrolyte Imbalance; acute renal failure; cancer; chronic kidney disease; drug nephrotoxicity; electrolytes; humans; kidney; multiple myeloma